uniQure (QURE) Tops Q2 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
RBC Capital on uniQure BV (QURE): 'Brain Safety Signal Unfortunate, But Stock Reaction Overdone'
August 8, 2022 12:59 PM EDTRBC Capital analyst Luca Issi reiterated an Outperform rating and $53.00 price target on uniQure BV (NASDAQ: QURE)
The analyst comments "Huntington's brain safety signal is unfortunate as it will delay the program, formal FDA clinical hold is possible and one patient has... More
Cowen on uniQure BV (QURE): 'We are hopeful the risk is manageable'
August 8, 2022 12:59 PM EDTCowen analyst Joseph Thome reiterated an Outperform rating on uniQure BV (NASDAQ: QURE).
The analyst comments "While the news is unfortunate and warrants additional investigation, we note that the U.S. data update remains on track for Q2:23 and a total of... More
Goldman Sachs Reiterates Buy Rating on uniQure BV (QURE)
August 8, 2022 12:57 PM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $51.00 price target on uniQure BV (NASDAQ: QURE).
The analyst comments "QURE released 2Q EPS and announced the postponement of procedures in the higher-dose cohort (6x1013vg) of the Ph1/2 US and Ph1b/2 EU studies of gene therapy AMT-130 in Huntingtons disease due to suspected unexpected... More
Credit Suisse Reiterates Outperform Rating on uniQure BV (QURE), 'Catalysts On-Track'
August 8, 2022 12:54 PM EDTCredit Suisse analyst Judah C. Frommer reiterated an Outperform rating and $51.00 price target on uniQure BV (NASDAQ: QURE)
The analyst comments "With 2Q22 earnings QURE disclosed pausing of enrollment in the high-dose cohort of its Ph1/2 AMT-130 (Huntingtons GT) trial following DSMB recommendation tied to 3 suspected unexpected severe adverse... More
